Sponsors
Blog
Chairman, GDS International
Sales and the 'Talent Magnet'
A lot is written about being a ‘Talent Magnet’, either as a company, or as President. It’s all good practice – listen, mentor, reward, provide clear goals and career maps. Good practice for the employer, but what about the employee?26 May 2011
White Papers
Focus Area: Research and Development
Combination tactics for orphan drug manufacturers
Marc Botteman explains how orphan drug manufacturers can combine pricing and market access strategies with health economics to optimise pricing and market access.
The impact of the growth of biopharmaceuticals on preclinical CROs
The only thing certain is change. This axiom holds true for many aspects of today’s world but it is a central tenet for drug development. Fifteen years ago, small molecules (chemically synthesised molecules designed to interact with a specific cellular receptor) represented the majority of pharmaceuticals under development. During the past 10 years, however, the number of therapies being developed that fall into the category of biopharmaceuticals has exploded, with predictions that the majority of therapies developed in the next 10 years will fall into this class.
Efficiency of drug development methodologies
With the discipline of drug development under the industry microscope, NGP talks to two leading experts to find out what techniques are being employed to push the efficiency of drug development methodologies.
Companion diagnostics and pharmaceuticals
Chris Moriarty highlights the need for flexible diagnostic partners in pushing personalised medicine.
UCL and ISIS uncover new aromatic molecule arrangement
What a recently uncovered molecule arrangement could mean for R&D and drug design in the world of pharmaceuticals.
Source: www.ngpharma.eu.com© 2012 GDS Publishing Ltd. All rights reserved.